華仁藥業(300110.SZ):上半年淨利預增146.81%-193.09%
格隆匯 7 月 7日丨華仁藥業(300110.SZ)披露2020年半年度業績預告,預計歸屬於上市公司股東的淨利潤3200-3800萬元,同比增長146.81%-193.09%。業績變動原因如下:
1、2020年上半年,由於疫情原因,公司生產、銷售活動受到不同程度的影響。公司積極應對困難,一方面全力做好疫情防控、復工復產工作,另一方面,抓住市場機會,加大新客户開發力度,進一步拓展增量市場。通過全員的共同努力,各項業務逐步恢復。
2、報告期內,面對疫情期間醫療防護物資嚴重短缺的局面,為踐行上市公司社會責任,充分發揮自身優勢,公司在目前的淨化廠房中改建醫用口罩生產線,生產醫用口罩等醫療防護用品,全力支持疫情防控工作。公司克服疫情期間的重重困難,短期內實現了口罩產品從項目立項到規模化生產、銷售。目前,公司的醫用外科口罩、一次性使用醫用口罩、醫用防護口罩、醫用一次性防護服分別取得了山東省藥品監督管理局核准簽發的《醫療器械註冊證》,醫用口罩已出口至部分國家,助力海外疫情防控。口罩業務貢獻了部分利潤,彌補了因疫情影響、輸液銷量下降對業績的影響。
3、其他原因:
2020年上半年,公司整體貸款規模較上年同期下降,財務費用同比減少;疫情期間,收到政府補助較上年同期增加。
報告期內公司歸屬上市公司股東的非經常性損益約為480萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.